Lipid interactions influence hepatitis C virus susceptibility and resistance to infection
Isaac Thom Shawa, David A. Sheridan, Daniel J. Felmlee, Matthew E. Cramp – 28 July 2017
Isaac Thom Shawa, David A. Sheridan, Daniel J. Felmlee, Matthew E. Cramp – 28 July 2017
Mohamed Safwan, Kelly M. Collins, Marwan S. Abouljoud, Reena Salgia – 28 July 2017 – Nonalcoholic fatty liver disease is becoming the leading cause of disease resulting in liver transplantation (LT). As a result of this trend, more LT candidates are presenting with prior history of bariatric surgery (BS). Over the last decade, 960 patients underwent LT at our institution; 11 (1.1%) had prior BS. The most common type of BS was Roux‐en‐Y gastric bypass (n = 9) with 1 sleeve gastrectomy and 1 jejunoileal bypass.
Robert W. Reindollar, Heather Roberts – 28 July 2017
William Bernal – 28 July 2017
Isaac Thom Shawa, David A. Sheridan, Daniel J. Felmlee, Matthew E. Cramp – 28 July 2017
Emma L. Culver, Eleanor Barnes – 28 July 2017
Ian A. Rowe – 28 July 2017
Pramod Kumar, Sunil Taneja, Virendra Singh – 28 July 2017
Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.
Lukas W. Unger, Gabriela A. Berlakovich, Michael Trauner, Thomas Reiberger – 28 July 2017 – Orthotopic liver transplantation (OLT) represents a curative treatment option for end‐stage liver disease (ESLD). Although epidemiology of ESLD has recently changed due to the rising prevalence of nonalcoholic fatty liver disease and the decreased burden of hepatitis C virus infections due to highly effective antiviral regimens, the management of portal hypertension (PHT) remains a clinical challenge in the pre‐ and post‐OLT setting.